SCHEMBL6318953

SCHEMBL6318953

CSCCCNC(=O)c1c(-c2coc3ccccc23)noc1N

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.37
HDAC6 Q9UBN7 4/20 0.36
HDAC1 Q13547 2/20 0.36
HDAC3 O15379 2/20 0.36
NCOR2 Q9Y618 2/20 0.36
HDAC4 P56524 1/20 0.36
HDAC2 Q92769 1/20 0.36
HDAC5 Q9UQL6 1/20 0.36
GAA P10253 2/20 0.35
TSHR P16473 1/20 0.35
MAPT P10636 1/20 0.35
GRK2 P25098 1/20 0.34
KMT2A Q03164 1/20 0.34
NAMPT P43490 1/20 0.34
IKBKE Q14164 1/20 0.34
TBK1 Q9UHD2 1/20 0.34
TNF P01375 1/20 0.34
CYP2C19 P33261 2/20 0.33
CA1 P00915 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6314864 0.89 MAOB (0.45) MAOBL3MBTL1HDAC6HDAC1HDAC3
SCHEMBL6316873 0.88 MAOB (0.44) MAOBL3MBTL1HDAC6HDAC1HDAC3
SCHEMBL6318968 0.87 MAOB (0.43) MAOBL3MBTL1HDAC6HDAC1HDAC3
SCHEMBL6316311 0.87 MAOB (0.43) MAOBL3MBTL1HDAC6HDAC1HDAC3
SCHEMBL6321222 0.87 MAOB (0.43) MAOBL3MBTL1HDAC6HDAC1HDAC3
SCHEMBL6318234 0.85 L3MBTL1 (0.52) L3MBTL1GAATSHRMAPTKMT2A
SCHEMBL6316190 0.84 L3MBTL1 (0.48) L3MBTL1TSHRMAPTCA1CA2
SCHEMBL6317244 0.84 KDM4E (0.40) MAOBL3MBTL1HDAC6HDAC3NCOR2
SCHEMBL6319017 0.84 MAOB (0.41) MAOBL3MBTL1GAATSHRMAPT
SCHEMBL6315149 0.83 RAB9A (0.45) L3MBTL1MAPTKMT2ACYP2C19CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 MAOB 1851/4885L3MBTL1 4176/4885HDAC6 985/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.